Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

Share this content:
In this study, researchers assessed the outcomes of pediatric and young adult patients with R/R HL to asses Bv-related toxicity.
In this study, researchers assessed the outcomes of pediatric and young adult patients with R/R HL to asses Bv-related toxicity.

Brentuximab vedotin (Bv) therapy led to an increased frequency of pulmonary toxicity among pediatric patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL), study findings published in the British Journal of Haematology have shown.

Bv, a widely accepted treatment for R/R HL, leads to improved outcomes and reduced toxicity overall compared with standard salvage regimens. Previous studies have however, demonstrated that Bv in combination with pulmonary toxic chemotherapy agents may have an additive effect, and its effect, particularly in pediatric patients, is unknown. 

For this retrospective study, researchers assessed the outcomes of 19 pediatric and young adult patients with R/R HL. Baseline clinical, demographic and health characteristics, such as prior pulmonary conditions, smoke conditions, and prior atopy were collected. Detailed treatment information, such as treatment exposure and cumulative doses of bleomycin, gemcitabine, and carmustine (BCNU) were also collected. 

Results showed that 36.8% (7 patients) received Bv, and analysis showed patients exposed to Bv had a nearly 4-fold increased risk of developing pulmonary toxicity compared with patients who were never exposed (P=.17). This finding, however, was not statistically significant, noted the researchers. 

“Given its clinical efficacy, Bv has been incorporated into more upfront and relapsed treatment protocols and understanding potential pulmonary toxicity will be critical to better detect short- and long-term complication of therapy,” they reported.

Reference

Faulk KE, Sopfe JM, Campbell K, et al. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin[published online September 10, 2018]. Br J Haematol. doi: 10.1111/bjh.15586

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs